The Phase II trial sponsored by Hospices Civils de Lyon investigates the efficacy of hyaluronic acid (HA) as a spacer to mitigate late rectal toxicities in patients undergoing hypofractionated radiotherapy for prostate cancer. With a focus on low- to intermediate-risk patients, this study could potentially enhance treatment tolerability and patient outcomes, thereby positioning HA as a valuable adjunct in prostate cancer radiotherapy. The reduction in treatment duration from 40 to 20 fractions may also appeal to healthcare providers seeking efficiency in treatment protocols. If successful, this could lead to broader adoption of HA in clinical practice, impacting market dynamics in the oncology space, particularly in radiotherapy adjuncts. Competitive analysis should consider existing spacer technologies and their market penetration, as well as the regulatory landscape for medical devices in oncology.